Liège start-up expands to US market with muscle fatigue metre
The US Food and Drug Administration (FDA) has approved a device developed by Liège start-up Myocene that measures muscle fatigue. The company also announced the establishment of a US subsidiary to support its expansion.
"The FDA approval is an important international recognition for our technology, which is already popular in Europe," said Myocene CEO Jean-Yves Mignolet in a press release. "It not only confirms our scientific and technological approach, which is unique in the world, but it also opens the doors to the American market, which is very dynamic in terms of high-level sports."
According to Mignolet, many US sports clubs have expressed interest in the device, which measures muscle fatigue using electrostimulation and delivers results in just two minutes. "The first devices will be delivered in the US in the coming weeks. We are clearly moving up a gear," he said.
"It opens the doors to the American market, which is very dynamic in terms of high-level sports"
The FDA approval was granted through the "de novo" pathway, reserved for innovative, low-risk devices without existing alternatives. Myocene claims its technology has no equivalent on the market. Last year, the company raised 3 million euros to accelerate growth and expand internationally.
Myocene's muscle fatigue metre © PHOTO BELGA HANDOUT
Related news
